US2946797A - N-aminotetrahydroisoquinolinium salts - Google Patents
N-aminotetrahydroisoquinolinium salts Download PDFInfo
- Publication number
- US2946797A US2946797A US755405A US75540558A US2946797A US 2946797 A US2946797 A US 2946797A US 755405 A US755405 A US 755405A US 75540558 A US75540558 A US 75540558A US 2946797 A US2946797 A US 2946797A
- Authority
- US
- United States
- Prior art keywords
- chloride
- salts
- compounds
- reaction
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- IYANYSZUKHQLKL-UHFFFAOYSA-N 3,4-dihydro-1h-isoquinolin-2-amine Chemical class C1=CC=C2CN(N)CCC2=C1 IYANYSZUKHQLKL-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 13
- 150000001450 anions Chemical group 0.000 description 13
- -1 saalicylate Chemical compound 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 150000001412 amines Chemical class 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 150000003512 tertiary amines Chemical class 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical class NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 238000011005 laboratory method Methods 0.000 description 3
- 150000002596 lactones Chemical group 0.000 description 3
- MPYHGNAJOKCMAQ-UHFFFAOYSA-N laudanine Chemical compound C1=C(O)C(OC)=CC=C1CC1C2=CC(OC)=C(OC)C=C2CCN1C MPYHGNAJOKCMAQ-UHFFFAOYSA-N 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- MPYHGNAJOKCMAQ-MRXNPFEDSA-N (R)-laudanine Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H]1C2=CC(OC)=C(OC)C=C2CCN1C MPYHGNAJOKCMAQ-MRXNPFEDSA-N 0.000 description 2
- OKORHWXYDBSYNO-INIZCTEOSA-N (S)-codamine Chemical compound C1=C(OC)C(OC)=CC=C1C[C@H]1C2=CC(O)=C(OC)C=C2CCN1C OKORHWXYDBSYNO-INIZCTEOSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- XXANNZJIZQTCBP-UHFFFAOYSA-N 4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinoline Chemical compound C1CN(C)CC2=C1C=C1OCOC1=C2OC XXANNZJIZQTCBP-UHFFFAOYSA-N 0.000 description 2
- HRSIPKSSEVRSPG-UHFFFAOYSA-N 6,7-dimethoxy-1,2-dimethyl-3,4-dihydro-1h-isoquinoline Chemical compound C1CN(C)C(C)C2=C1C=C(OC)C(OC)=C2 HRSIPKSSEVRSPG-UHFFFAOYSA-N 0.000 description 2
- JZUTXVTYJDCMDU-MOPGFXCFSA-N Hydrastine Chemical compound CN1CCC2=CC=3OCOC=3C=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 JZUTXVTYJDCMDU-MOPGFXCFSA-N 0.000 description 2
- CRAVBINFWZGLSC-UHFFFAOYSA-N Hydrastine Natural products COC1=C(OC)C2C(C=C1)C(OC2=O)C3N(C)CCc4cc5OCOc5cc34 CRAVBINFWZGLSC-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- DQPBABKTKYNPMH-UHFFFAOYSA-N amino hydrogen sulfate Chemical compound NOS(O)(=O)=O DQPBABKTKYNPMH-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 159000000009 barium salts Chemical class 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical group OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- JZUTXVTYJDCMDU-UHFFFAOYSA-N d-alpha-hydrastine Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 JZUTXVTYJDCMDU-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 229930005369 hydrastine Natural products 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- ZGCHATBSUIJLRL-UHFFFAOYSA-N hydrazine sulfate Chemical compound NN.OS(O)(=O)=O ZGCHATBSUIJLRL-UHFFFAOYSA-N 0.000 description 2
- 229910000377 hydrazine sulfate Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 150000001261 hydroxy acids Chemical class 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229940075930 picrate Drugs 0.000 description 2
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- NGZXDRGWBULKFA-NSOVKSMOSA-N (+)-Bebeerine Chemical compound C([C@@H]1N(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 NGZXDRGWBULKFA-NSOVKSMOSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- ZBKFZIUKXTWQTP-QGZVFWFLSA-N Armepavine Chemical compound C([C@H]1N(C)CCC=2C=C(C(=CC=21)OC)OC)C1=CC=C(O)C=C1 ZBKFZIUKXTWQTP-QGZVFWFLSA-N 0.000 description 1
- ZBKFZIUKXTWQTP-KRWDZBQOSA-N Armepavine Natural products C([C@@H]1N(C)CCC=2C=C(C(=CC=21)OC)OC)C1=CC=C(O)C=C1 ZBKFZIUKXTWQTP-KRWDZBQOSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- DFOCUWZXJBAUSQ-URLMMPGGSA-N Berbamine Chemical compound C([C@@H]1N(C)CCC=2C=C(C(OC=3C(OC)=C(OC)C=C4CCN(C)[C@@H](C=34)CC=3C=C(C(=CC=3)O)O3)=CC=21)OC)C1=CC=C3C=C1 DFOCUWZXJBAUSQ-URLMMPGGSA-N 0.000 description 1
- DFOCUWZXJBAUSQ-UHFFFAOYSA-N Berbamine Natural products O1C(C(=CC=2)O)=CC=2CC(C=23)N(C)CCC3=CC(OC)=C(OC)C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C1C=C2 DFOCUWZXJBAUSQ-UHFFFAOYSA-N 0.000 description 1
- IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- OKORHWXYDBSYNO-UHFFFAOYSA-N Codamine Natural products C1=C(OC)C(OC)=CC=C1CC1C2=CC(O)=C(OC)C=C2CCN1C OKORHWXYDBSYNO-UHFFFAOYSA-N 0.000 description 1
- AQASRZOCERRGBL-UHFFFAOYSA-N Dauricine Natural products CN1CCC2=CC(OC)=C(OC)C=C2C1CC1=CC=C(O)C(OC2=CC=C(C=C2)CC2N(C)CCC=3C=C(C(=CC=32)OC)OC)=C1 AQASRZOCERRGBL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- XKIFTXQTBJZSEZ-UHFFFAOYSA-N Gnoscopine Natural products COc1ccc2C(OC(=C)c2c1OC)C3N(C)CCc4cc5OCOc5c(OC)c34 XKIFTXQTBJZSEZ-UHFFFAOYSA-N 0.000 description 1
- 241000735429 Hydrastis Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LYBYYVXQSFDBQO-INIZCTEOSA-N L-(+)-Laudanidine Natural products O(C)c1c(OC)cc2c([C@H](Cc3cc(O)c(OC)cc3)[N+](C)CC2)c1 LYBYYVXQSFDBQO-INIZCTEOSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000011096 Papaver Nutrition 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- 241001417494 Sciaenidae Species 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229940091179 aconitate Drugs 0.000 description 1
- GTZCVFVGUGFEME-UHFFFAOYSA-N aconitic acid Chemical compound OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 1
- RAESLDWEUUSRLO-UHFFFAOYSA-O aminoazanium;nitrate Chemical compound [NH3+]N.[O-][N+]([O-])=O RAESLDWEUUSRLO-UHFFFAOYSA-O 0.000 description 1
- DLRICKJDQFHZGI-UHFFFAOYSA-N ammonia;chloroamine Chemical compound N.ClN DLRICKJDQFHZGI-UHFFFAOYSA-N 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 description 1
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- NGZXDRGWBULKFA-VSGBNLITSA-N curine Chemical compound C([C@H]1N(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 NGZXDRGWBULKFA-VSGBNLITSA-N 0.000 description 1
- IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 description 1
- AQASRZOCERRGBL-ROJLCIKYSA-N dauricine Chemical compound CN1CCC2=CC(OC)=C(OC)C=C2[C@H]1CC1=CC=C(O)C(OC2=CC=C(C=C2)C[C@H]2N(C)CCC=3C=C(C(=CC=32)OC)OC)=C1 AQASRZOCERRGBL-ROJLCIKYSA-N 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- NBEMQPLNBYYUAZ-UHFFFAOYSA-N ethyl acetate;propan-2-one Chemical compound CC(C)=O.CCOC(C)=O NBEMQPLNBYYUAZ-UHFFFAOYSA-N 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000000574 ganglionic effect Effects 0.000 description 1
- 229940114119 gentisate Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-O hydrazinium(1+) Chemical compound [NH3+]N OAKJQQAXSVQMHS-UHFFFAOYSA-O 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 238000005649 metathesis reaction Methods 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002511 phenobarbital sodium Drugs 0.000 description 1
- WRLGYAWRGXKSKG-UHFFFAOYSA-M phenobarbital sodium Chemical compound [Na+].C=1C=CC=CC=1C1(CC)C(=O)NC([O-])=NC1=O WRLGYAWRGXKSKG-UHFFFAOYSA-M 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000036584 pressor response Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- JNMRHUJNCSQMMB-UHFFFAOYSA-N sulfathiazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CS1 JNMRHUJNCSQMMB-UHFFFAOYSA-N 0.000 description 1
- 229960001544 sulfathiazole Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003526 tetrahydroisoquinolines Chemical class 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
- C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
Definitions
- X is an anion bearing the charge n; It also indicates the number of 'univalent cations required to balance the charge'on X.
- Example I A solution of 25 g. of narcotine in 200 ml. ofchloroform was treated over a period of 90 minutes with gaseous chloramine formed in 60-70% yield from 22 g. of chlorine using the Sisler et al. generator previously discussed. After standing overnight, the reaction mixture was filtered from the resultant ammonium chloride and the filtrate evaporated to dryness. The 29 g. of light tan residue obtained wasapproximately a 50-50 mixture of unreacted narcotine and N-aminonarcotinium chloride. The product was isolated by dissolving the residue in acetone, filtering and pouring the filtrate into a five volume excess of ethyl acetate. Filtration gave about g.
- Examples IX and X N-aminonarcotinium chloride was dissolved in physiological saline'at concentrations of and 50 mg./ml. and administered to unstarved male albino mice at doses of 50, 300, 400 and 500 mg./kg.
- the acute intraperitoneal LD at 48 hours appeared to be approximately 400 mg./kg.
- N-aminonarcotinium picrate N-aminonarcotinium picrate.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
I 2,946,797 N-AMINOTETRAHYDROISOQIHNOLINIUM SALTS Bernard Rudner, Pittsburgh, Pa., assignor to W. R. (grace 8: Co -New York, N.Y., a corporation of Connecticut No Drawing. Filed Aug. 18, 1958, Ser. No. 755,405
7 Claims. (Cl. 260-286) g This invention relates to organic compounds which contain a quaternized nitrogen as part of their structure. In one specific aspect, it relates to hydrazin-ium. derivatives of tetrahydroisoquinoline which may be called N- aminotetrahydroisoquinolinium salts.
It is an object of the present invention to provide a new class of hydrazin-inm salts, useful for pharmaceutical and other purposes, which can be made in commercial quantities.
In accordance with the present invention, there has been discovered a new. and useful generic class of hydrazinium compounds corresponding to the general formula:
group, an aromatic carboxylicacid group and an aliphatic hydrogens. I
When B is a five-membered lactone ring is formed corresponding to the hydroxy acid in which the carboxyl group is attached,-
to the aromatic ring and the hydroxyl group is present on the methylene groupconnecting the aromatic ring with the tetrahydroisoquinoline-structure. X is an anion bearing the charge n; It also indicates the number of 'univalent cations required to balance the charge'on X.
When my compounds are used for pharmaceutical purposes, X must be a pharmaceutically acceptable anion. The primary attributes of's-uch an anion are nontoxicity and pharmaceutical compatibility. Otherwise, the choice of the anion is of little consequence, since the primary activity of my novel compounds resides in the cation;
The salts obtained by variation of the anionmay in some cases have special advantages due to solubility, ease of crystallization, lack. of objectionable taste and theiike, but'these considerations .are allsubsidiary to the char:
acteristics of the cation which are. independent of the 2,946,797 Patented July 26, 1960 character of the anion. Hence all variations of X are considered equivalent for the purpose of the present invention. Specific, but non-limiting, variants of X are as follows: chloride, bromide, iodide, sulfate, bisulfate, acetate, saalicylate, valerate, oleate, phenate, 'laurate, borate, benzoate, lactate, nitrate, di-glycolate, phosphate, phenylethylbarbiturate, o-acetoxybenzoate, citrate, dialkylbarbiturate, sulfathiazole, theophyllinate, urate, maleate, fumarate, succinate, tartrate, diethylbarbit-urate, penicillinate, camphorate, salicylamide, diphenylhydantoin, carbonate,- cacodylate, aconitate, sulfamate, gentisate, malate and the like. 7
One method of preparing the novel compounds of my invention is to react chloramine with the tertiary amine corresponding to the desiredhydrazinium compound; the product is isolated and purified by standard laboratory techniques. Since many of the amines are commercially available as their salts, the hydrochloride being the most common, it has been found convenient to treat aqueous solutions of the amine salts with base and extract the free amine with a solvent such as chloroform. After treatment of the extract witha conventional drying agent, the solution is ready for chloramination. While'chloramine is most advantageously prepared as a gaseous chloramine-ammonia mixture obtained from a generator constructed according to the teachings of Sisler et' al., U.S.
- Patent 2,710,248, other methods are equally adaptable ditions of mixing at low temperatures.
for the purpose of the present invention. For instance, chloramine can be made by reacting chlorine with an excess of ammonia in carbon tetrachloride or similar halogenated hydrocarbon solvents under controlled conf Such a process is fully described in U.S. Patent 2,678,258 to John F. Haller. Another efl'ective procedure is that of Cole man et a1. fully described in Inorganic Syntheses, vol; I, 59 (1939). Alternatively, the chloramine can be formed in the presence of the amine as described in the copending application Serial No. 605,230 filed August 20, 1956, which teaches the reaction of chlorine and a' tertiary amine in the presence of excess ammonia. For simplicity, when both the amine and the product are soluble in the same inert solvent, e.g., chloroform, chlora mine may be formed in sit-u by this method right in the solution-containing the reactant tertiary amine. In general, the choice of solvent is. one of economy and simplicity. When preformed chloramine is used and good absorption is required for efficient reaction, it has been found desirable to bubble chloramine through a long column of a solution comprising the tertiary amine dissolved in relatively cheap inert solvent. By inert solvent it is meant a solvent unreactive under the condition 'of the reaction. Solvents which serve this purpose include hydrocarbons, e.g., heptane, c'yclohexane,
the reaction is conducted in anhydrous solution, the prod-' not often precipitates as the reaction progresses. In aqueous solution, however, it is usually necessary to concentrate or to evaporate to dryness in order to isolate the product.
Another-method of preparing the novel compounds ofmy invention is the reaction of hydroxylamine-o-sulfonic acid with tertiary amines which produces the hydra ziniumsulfate corresponding to the tertiary amine used.
Preferably the appropriate tertiary amine and hydroxylamine-o-sulfonic acid are allowed to react or are heated together in the presence of an alcoholic solvent but eX- cess amine or other suitable solvents may be used. Even though the use of a solvent is not required, superior results are obtained with a solvent because of the extremely exothermic reaction that quite often results. A frequent purification step is the treatment of the reaction mixture with a basic substance such as sodium carbonate to remoye ,acidic constituents from the product hydrazinium sulfate which is essentially neutral and stable to the action of base. Further purification is effected by standard laboratory techniques.
It is obvious that not all of the novel hydrazinium compounds of my invention are capable of being prepared directly as shown above. In order to provide the other useful salts of the present invention, it is necessary to prepare the compounds containing anions other than chloride or sulfate by metathesis. Many of the anions described supra can be obtained by mixing aqueous solutions" of the hydrazinium chloride with appropriate reagents. More often than not, the desired product precipitates directly as the reaction progresses. This is the casewhere the new salt being formed is less soluble or insoluble in water. Other metathetical approaches are available and the method selected depends on experimental convenience, costs of reagents and the differences inphysical properties between the product and the starting material to be utilized in their separation. Reaction of a hydrazinium halide with a soluble silver salt, such as silver nitrate, results in the precipitation of silver halide and the formation of the hydrazinium nitrate. In an analogous manner, treatment of the sulfate with a soluble barium salt results in the precipitation of barium sulfate and conversion to the anion of the barium salt. Quite often the appropriate reactants are heated together in the absence of a solvent and the product isolated by standard laboratory techniques. Another approach independent of the formation of an insoluble solid, is to react the halide with an excess of the desired anion as its acid; hydrogen halide is evolved as the new salt is formed. When it is necessary to prepare a very soluble salt, the reaction of the hydrazinium hydroxide with'equivalent amounts of the appropriate acid may be utilized; this approach is also used for the preparation of very pure compounds. (Subjecting a hydrazinium halide to the action of moist silver oxide will give the hydrazinium hydroxide).
, .Suitable starting amines for the practice of my invention include narcotine, gnoscopine, hydrastine, laudanine, laudanidine, landanosine, codamine, bicucine and bicuculline. Related amines believed to react in a similar way are bebeerine, curine, berbamine, dauricine, armepavine, carnegine and hydrocotarnine. The starting amines are mostly naturally occurring alkaloids isolated from plants of genus Papaver and genus Hydrastis. The hydrazinium compounds synthesized from the above amines have minimum toxicity and exhibit strong hypotensive properties.
The scope and utility of my invention is further illustrated by the following examples:
Example I 'A solution of 25 g. of narcotine in 200 ml. ofchloroform was treated over a period of 90 minutes with gaseous chloramine formed in 60-70% yield from 22 g. of chlorine using the Sisler et al. generator previously discussed. After standing overnight, the reaction mixture was filtered from the resultant ammonium chloride and the filtrate evaporated to dryness. The 29 g. of light tan residue obtained wasapproximately a 50-50 mixture of unreacted narcotine and N-aminonarcotinium chloride. The product was isolated by dissolving the residue in acetone, filtering and pouring the filtrate into a five volume excess of ethyl acetate. Filtration gave about g. of white powder melting at 230 C. and 97% pure by chloride titration; unreacted amine and more product were recovered by evaporation of the filtrate. Recrystallization of the product from acetone-ethyl acetate gave fine white needles melting'at 230 C. soluble in water, alcohol salt of the hydrolyzed lactone.
and chloroform, somewhat in acetone and dimethylformamide and insoluble in benzene. Calculated for N-aminonarcotinium chloride (C H N O Cl): C, 56.8%; H, 5.43%; N, 6.03%; and Cl, 7.68%. Found: C, 57.0%; H, 5.68; N, 6.05%, and Cl, 8.17%.
Examples 11 and III onto Example IV A solution of 0.22 g. of N-aminonarcotinium chloride in 10 ml. of deionized and deaerated water was treated with an equivalent amount of sodium hydroxide as a 0.1 N solution in deaerated water. The, reaction mixture at 4050 C. was evaporated to dryness in a stream of nitrogen; the evaporation was repeated after 20 ml. more treated water was added. The residual thick yellow oil, soluble in water and alcohol, was believed to be the sodium Heating with anhydrous hydrogen chloride first converted it to the hydroxy acid and then to the lactone identical with the product of Example I as illustrated below:
on no-on H01 HO-CH I 'Naooo 11000 01130 OHaO OCH. OCH:
Example V An equimolar solution of N-aminonarcotinium chloride Example VI A solution of 25 g. of hydrastine dissolved in'chloroform was treated with .gaseous chloramine as in Example I. The reaction mixture was filtered from ammonium chloride and evaporated to a water and chloroform soluble yellow product. Purification was effected by redissolving the residue in chloroform and adding the solution to a ten volume excess of benzene. Filtration gave N- aminohydrastinium chloride as a yellow powder melting 179-180 0.; its structural formula is given below:
0 I l /CHs NHfCl- O-- H o= CHaO OCH;
Examples VII and VIII Separate portions of N-aminohydrastinium chloride were dissolved in water and treated with aqueous potassium hexafluorophosphate and with saturated aqueous picn'c acid. The resultant precipitates were collected by filtration and dried to give N-aminohydrastinium hexafluorophosphate (M.P. 290 C.) and N-aminohydrastinium picrate (M.P. ca. 125 C.) respectively.
Examples IX and X N-aminonarcotinium chloride was dissolved in physiological saline'at concentrations of and 50 mg./ml. and administered to unstarved male albino mice at doses of 50, 300, 400 and 500 mg./kg. The acute intraperitoneal LD at 48 hours appeared to be approximately 400 mg./kg. I
A mongrel female dog weighing 8.8 kg. was anesthetized by the intraperitoneal administration of phenobarbital sodium and surgery was supported with intravenous pentobarbital sodium. The carotid artery was cannulated and connected to a mercury manometer for recording blood pressure and a Pfeifier Cannula was inserted into the trachea and connected to a Marey tambour for recording respiration. A femoral vein was exposed for introduction of the test material. N-aminonarcotinium chloride was dissolved in physiological saline at concentrations of 2.0 and mg./ml. The dog received intravenous doses of 0.05, 0.25, 1.25, 6.25 and 11 mg./kg. over a period of approximately four hours. A moderate but transient fall in blood pressure was observed following the 1.25 mg./kg. dose. Marked and precipitous falls in blood pressure with apnea were observed after doses of 6.25 and 11 mg./kg., the duration of the hypotensive action was from to 60 minutes. There were no significant effects on the blood pressure responses to acetylcholine, epinephrine or nor-epinephrine at any time during the study. The pressor response to nicotine was abolished following 1.25 mg./kg. dose, suggesting ganglionic depressant activity.
I claim:
1. New chemical compounds having the general formula:
6 wherein R is lower alkoxy, X is a pharmaceutically acceptable anion and n is an integer less than four.
2. New chemical compounds having the general formula:
15 CHsO OCH n wherein R is hydrogen, X is a pharmaceutically acceptable anion and n is an integer less than four.
20 3. New chemical compounds having the general formula:
wherein R is lower alkoxy, X is a pharmaceutically acceptable anion and n is an integer less than four.
4. As a new chemical compound, N-aminonarcotinium chloride.
5. As a new chemical compound, N-aminonarcotinium picrate.
.6. As a new chemical compound, N-aminohydrastinium chloride. L171. New chemical compounds having the general form a:
/OH: R H
R NH: H Xuand hydroxyl; R is selected from the group consisting of hydrogen and carboxyl; R and R taken collectively are carbonyloxy; X is a pharmaceutically acceptable anion; and n is an integer less than four.
No references cited.
UNITED STATES PATENT OFFICE Certificate of Correction July 26, 1960 Patent No. 2,946,797
Bernard Rudner It is hereby certified that error appears in the above numbered patent requiring correction and that the said Letters Patent should read as corrected below.
Column 6, lines 45 to 55, the formula should appear as shown below instead of as in the patent:
/CH: R
R NH:
RI H X! Signed and sealed this 9th day of May 1961.
[SEAL] Attest:
ERNEST W. SWIDER, DAVID L. LADD, Commz'ssz'oner of Patents.
Attesting Oficer.
Claims (1)
- 7. NEW CHEMICAL COMPOUNDS HAVING THE GENERAL FORMULA:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US755405A US2946797A (en) | 1958-08-18 | 1958-08-18 | N-aminotetrahydroisoquinolinium salts |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US755405A US2946797A (en) | 1958-08-18 | 1958-08-18 | N-aminotetrahydroisoquinolinium salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US2946797A true US2946797A (en) | 1960-07-26 |
Family
ID=25039001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US755405A Expired - Lifetime US2946797A (en) | 1958-08-18 | 1958-08-18 | N-aminotetrahydroisoquinolinium salts |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US2946797A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3314958A (en) * | 1964-06-29 | 1967-04-18 | Millmaster Onyx Corp | Quaternary ammonium enolates of urea derivatives |
| US3624082A (en) * | 1966-05-26 | 1971-11-30 | Swift & Co | Process for making 2-hydroxy-3-alkoxy quaternary ammonium propane salts |
-
1958
- 1958-08-18 US US755405A patent/US2946797A/en not_active Expired - Lifetime
Non-Patent Citations (1)
| Title |
|---|
| None * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3314958A (en) * | 1964-06-29 | 1967-04-18 | Millmaster Onyx Corp | Quaternary ammonium enolates of urea derivatives |
| US3624082A (en) * | 1966-05-26 | 1971-11-30 | Swift & Co | Process for making 2-hydroxy-3-alkoxy quaternary ammonium propane salts |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US2893996A (en) | N-amino derivatives of tropine alkaloids | |
| US2946797A (en) | N-aminotetrahydroisoquinolinium salts | |
| US3733330A (en) | Benzomorphan derivatives | |
| US2948730A (en) | 8-aminotropanium compounds | |
| SU927111A3 (en) | Process for producing oxime-esters or their salts | |
| US3847924A (en) | Certain scopolammonium compounds | |
| US2957873A (en) | Aralkylhydrazinium salts | |
| US2909530A (en) | Physostigmine derivatives | |
| EP0009608B1 (en) | N-phenethylacetamide compounds, processes for their preparation and therapeutic compositions containing them | |
| US2946796A (en) | Salts of ergot alkaloids | |
| US2957876A (en) | N-aminopiperidinium salt | |
| Folkers et al. | Erythrina alkaloids. VIII. Studies on the constitution of erythramine and erythraline | |
| US2957866A (en) | Strychnos hydrazinium compounds | |
| US2933500A (en) | Nu-aminoindolobenzoquinolizinium compounds | |
| US3268508A (en) | Process for the preparation of kanamycin-nu, nu'-dimethanesulfonic acid | |
| US2976319A (en) | Carbanilinoalkylhydrazinium salts | |
| DK171299B1 (en) | 4-Amino-6,7-dimethoxy-2- (1,2,3,4-tetrahydroisoquinolin-2-yl) quinoline compounds, pharmaceutical compositions containing them and their use in the preparation of antiarrhythmic drugs | |
| US2970999A (en) | Nu-aminoemetinium compounds | |
| US2967865A (en) | Piperazinium salts | |
| US4143143A (en) | Substituted imidazo[5,1-a]isoquinolines | |
| US2946795A (en) | Apomorphinium salts | |
| US2967864A (en) | Quaternized morphine derivatives | |
| US3880862A (en) | 6{62 -Azido-17-cycloalkylmethyl-4,5{60 -epoxymorphinan-3-ols | |
| US2946789A (en) | Bis morpholinium salts | |
| US3202668A (en) | Nu-aminophenindaminium salts |